85 related articles for article (PubMed ID: 1465740)
1. Metabolic mapping of the synergism between MK-801 and SKF 38393 in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
Pontieri FE; Morelli M; Orzi F; Terenzi R; Di Chiara G
Synapse; 1992 Dec; 12(4):255-60. PubMed ID: 1465740
[TBL] [Abstract][Full Text] [Related]
2. Local cerebral glucose utilization after D1 receptor stimulation in 6-OHDA lesioned rats: effect of sensitization (priming) with a dopaminergic agonist.
Morelli M; Pontieri FE; Linfante I; Orzi F; Di Chiara G
Synapse; 1993 Mar; 13(3):264-9. PubMed ID: 8098880
[TBL] [Abstract][Full Text] [Related]
3. N-methyl-D-aspartate receptor blockade differentially modifies regional cerebral metabolic responses to D1 and D2 dopamine agonists in rats with a unilateral 6-hydroxydopamine lesion.
Engber TM; Anderson JJ; Boldry RC; Kuo S; Chase TN
Neuroscience; 1993 Jun; 54(4):1051-61. PubMed ID: 8101981
[TBL] [Abstract][Full Text] [Related]
4. Nigrostriatal lesion and dopamine agonists affect firing patterns of rodent entopeduncular nucleus neurons.
Ruskin DN; Bergstrom DA; Walters JR
J Neurophysiol; 2002 Jul; 88(1):487-96. PubMed ID: 12091570
[TBL] [Abstract][Full Text] [Related]
5. Nigrostriatal lesion alters neurophysiological responses to selective and nonselective D-1 and D-2 dopamine agonists in rat globus pallidus.
Carlson JH; Bergstrom DA; Demo SD; Walters JR
Synapse; 1990; 5(2):83-93. PubMed ID: 2309160
[TBL] [Abstract][Full Text] [Related]
6. Influence of previous exposure to levodopa on the interaction between dizocilpine and dopamine D1 and D2 agonists in rats with 6-hydroxydopamine-induced lesions.
Boldry RC; Chase TN; Engber TM
J Pharmacol Exp Ther; 1993 Dec; 267(3):1454-9. PubMed ID: 7903390
[TBL] [Abstract][Full Text] [Related]
7. Electrophysiological effects of SKF 38393 in rats with reserpine treatment and 6-hydroxydopamine-induced nigrostriatal lesions reveal two types of plasticity in D1 dopamine receptor modulation of basal ganglia output.
Huang KX; Walters JR
J Pharmacol Exp Ther; 1994 Dec; 271(3):1434-43. PubMed ID: 7996456
[TBL] [Abstract][Full Text] [Related]
8. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
Sonsalla PK; Manzino L; Heikkila RE
J Pharmacol Exp Ther; 1988 Oct; 247(1):180-5. PubMed ID: 2971797
[TBL] [Abstract][Full Text] [Related]
9. N-methyl-D-aspartate receptor blockade attenuates D1 dopamine receptor modulation of neuronal activity in rat substantia nigra.
Huang KX; Bergstrom DA; Ruskin DN; Walters JR
Synapse; 1998 Sep; 30(1):18-29. PubMed ID: 9704877
[TBL] [Abstract][Full Text] [Related]
10. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
Hu XT; White FJ
Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
[TBL] [Abstract][Full Text] [Related]
11. Failure of MK-801 to suppress D1 receptor-mediated induction of locomotor activity and striatal preprotachykinin mRNA expression in the dopamine-depleted rat.
Campbell BM; Kreipke CW; Walker PD
Neuroscience; 2006; 137(2):505-17. PubMed ID: 16289829
[TBL] [Abstract][Full Text] [Related]
12. Blockade of NMDA receptors by MK-801 reverses the changes in striatal glutamate immunolabeling in 6-OHDA-lesioned rats.
Robinson S; Krentz L; Moore C; Meshul CK
Synapse; 2001 Oct; 42(1):54-61. PubMed ID: 11668591
[TBL] [Abstract][Full Text] [Related]
13. Evidence for involvement of brain dopamine and other mechanisms in the behavioral action of the N-methyl-D-aspartic acid antagonist MK-801 in control and 6-hydroxydopamine-lesioned rats.
Criswell HE; Johnson KB; Mueller RA; Breese GR
J Pharmacol Exp Ther; 1993 May; 265(2):1001-10. PubMed ID: 8098756
[TBL] [Abstract][Full Text] [Related]
14. MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons.
Van De Witte SV; Groenewegen HJ; Voorn P
Synapse; 2002 Jan; 43(1):1-11. PubMed ID: 11746728
[TBL] [Abstract][Full Text] [Related]
15. Modulation of dopamine D1-mediated turning behavior and striatal c-fos expression by the substantia nigra.
Fenu S; Carta A; Morelli M
Synapse; 1995 Apr; 19(4):233-40. PubMed ID: 7792718
[TBL] [Abstract][Full Text] [Related]
16. Substantia nigra glutamate antagonists produce contralateral turning and basal ganglia Fos expression: interactions with D1 and D2 dopamine receptor agonists.
McPherson RJ; Marshall JF
Synapse; 2000 Jun; 36(3):194-204. PubMed ID: 10819899
[TBL] [Abstract][Full Text] [Related]
17. Blockade of N-methyl-D-aspartate receptors potentiates dopaminergic responses in the 6-OHDA model of Parkinson: differential role of D-1 and D-2 receptors.
Morelli M; Fenu S; Di Chiara G
Neurochem Int; 1992 Mar; 20 Suppl():261S-264S. PubMed ID: 1365438
[TBL] [Abstract][Full Text] [Related]
18. Reformation of the nigrostriatal pathway by fetal dopaminergic micrografts into the substantia nigra is critically dependent on the age of the host.
Bentlage C; Nikkhah G; Cunningham MG; Björklund A
Exp Neurol; 1999 Sep; 159(1):177-90. PubMed ID: 10486186
[TBL] [Abstract][Full Text] [Related]
19. Self-injurious behavior and dopaminergic neuron system in neonatal 6-hydroxydopamine-lesioned rat: 2. Intracerebral microinjection of dopamine agonists and antagonists.
Okamura H; Murakami T; Yokoyama C; Nakamura T; Ibata Y
J Pharmacol Exp Ther; 1997 Feb; 280(2):1031-7. PubMed ID: 9023320
[TBL] [Abstract][Full Text] [Related]
20. Impact of metyrapone on MK-801-induced alterations in the rat dopamine D1 receptors.
Czyrak A; Maćkowiak M; Fijał K; Chocyk A; Wedzony K
Pol J Pharmacol; 1997; 49(5):305-16. PubMed ID: 9566029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]